Press Enter to search · Esc to close
Two new commentaries spotlight a single signaling molecule as a clean lever on age-related inflammation. The mouse data are striking. The human verdict is years away.
Consumer biological-age tests promise a number that tells you how fast you're aging. A new analysis suggests the signal underneath that number isn't quite what we thought.
A single mechanism paper gives a long-suspected 'longevity vitamin' its first credible story — in worms and aged rats. Humans are not worms.
A new whole-exome analysis of 1,245 long-lived Germans finds rare variants clustering in the mTOR pathway — the same one rapamycin targets — offering rare human evidence for a mechanism mostly studied in animals.
A new wave of peer-reviewed evidence shows GLP-1 drugs reaching further into metabolic medicine—while exposing risks that busy men should know before they fill the prescription.
Two new studies sharpen the picture of mTOR as an aging lever — pointing toward more precise ways to dial it down than blunt suppression.
A new clinical clock called LinAge2 is trained to predict survival, not just guess your age — a quiet but meaningful shift for anyone paying for an epigenetic age test.
A new European synthesis maps the levers — personal, clinical, and environmental — that may compress the years we spend sick at the end of a longer life.
Two 2025 studies converge on measurable biological signatures that set centenarians—and long-lived mammals—apart. The evidence is intriguing, the mechanisms partial, the hype unwarranted.
The same cellular switch that supplement brands sell as 'longevity insurance' may quietly favor lung tumors. A new GeroScience analysis forces a harder look at sulforaphane, curcumin, and the broader NRF2 boom.